Where current care doesn’t always match current evidence — and what patients can do about it.
Here's what the published research doesn't yet answer.
Gap 1: Volume-loss deformities are often missed
65% of PD patients have hourglass, indentation, or distal-tapering deformities (Margolin 2018, n=128) — yet routine PD evaluation often doesn't formally assess for them. They're independently associated with axial instability (OR 3.5), psychological distress (OR 2.6), and decreased sexual activity (OR 2.7) — not just curvature surrogates. If your treatment plan doesn't address volume loss, your plan may be missing a significant component of your condition.
Gap 2: Verapamil at 3-month intervals has no published support
Published verapamil protocols use weekly to biweekly intervals (Levine 2002, Favilla 2017). 3-month intervals appear in zero published studies — controlled or uncontrolled. If your urologist has you on a non-standard schedule for a treatment with no controlled curvature evidence, ask explicitly: 'What's the published basis for this interval?' 21% of US urologists currently use AUA-discouraged treatments (Brant 2023).
Gap 3: No discussion of alternatives = no informed consent
Only 60% of urologists perform thorough pre-treatment assessment including in-office curvature measurement. Fellowship-trained sexual medicine specialists do thorough evaluations 85% of the time vs 54% for non-fellowship-trained (P=.003). 81% of urologists treating PD have no fellowship training. If alternatives weren't discussed (CCH, HA, traction, surgery), informed consent didn't happen — regardless of paperwork signed.
Gap 4: Refusing outside imaging delays care during the most critical window
Outside imaging refusal is a documented systemic pattern — patient lock-in, billing capture, scheduling control. For PD specifically, every month of delay during active phase is a month of potential progression. If a Doppler is available elsewhere in 2 weeks but your urologist requires their own in 3 months, that adds 3 months to a timeline that's actively progressing.
Gap 5: When the verbal summary doesn't match the written report
Verbal clinical communication often diverges from formal documentation — a recognized quality concern across all medical specialties. For PD, treatment decisions should be based on documented findings, not verbal impressions. If something the doctor says doesn't match the report (e.g., 'reduced flow' verbally, but Doppler says all parameters normal), ask for clarification — one of them is wrong.
Gap 6: Practice lags evidence — sometimes by a decade or more
The time for landmark clinical evidence to change clinical practice is documented as substantial across multiple medical specialties. For PD: Favilla 2017 demonstrated zero verapamil curvature benefit in a double-blind RCT — yet verapamil remains widely prescribed in 2025. Brant 2023 (n=145) found 21% of US urologists currently use AUA-discouraged treatments. If your doctor's reference points are from before 2015, calibrate accordingly.
Gap 7: 3-minute encounters can't deliver informed consent
Meaningful informed consent requires understanding diagnosis, proposed treatment, alternatives, evidence for and against each, and risks. For PD — multiple options, phase-dependent selection, evidence-graded guidelines with cross-society disagreements — this is structurally impossible in a 3-minute encounter. If your PD encounter takes less than 10 minutes and doesn't include a discussion of alternatives, you may not be receiving informed-consent-grade care.
Gap 8: Injectable without mechanical adjunct may be missing the mechanism
Across CCH studies, mechanical adjunct (modeling, traction) appears necessary for curvature correction. A separate Phase IIb study (cited via secondary IMPRESS review literature) reported no difference between CCH and placebo in non-modeling arms. Studies with intensive multimodal mechanical adjunct (Capece 2018, n=135) report higher response rates than studies with standard modeling alone. If your doctor prescribes an injection without specifying a modeling/traction protocol, understanding the reasoning may be worth discussing.
How common are these gaps? Most are documented at clinically significant rates
Volume-loss unassessed: 65% of patients have it (Margolin 2018), assessment rate unknown. AUA-discouraged treatments: 21% of US urologists currently use them (Brant 2023). No options discussion: 40% of urologists don't do thorough pre-treatment assessment. No fellowship training: 81% of urologists treating PD have no andrology fellowship. Survey response rate (Brant): 1.2% — non-respondent skew likely underestimates the gap. Most US data; community urology practices may have different gap profiles.
What this document is: A research-backed analysis of common gaps in PD care, drawn from published physician surveys and confirmed by a real patient's experience. Every claim cites a specific study with author, year, sample size, and source type.
For the underlying evidence behind each gap, see the Evidence Reference (Document B). For how this analysis was conducted, see our Process & Transparency page.
What this document is NOT: An attack on any individual doctor. Most PD care gaps are systemic — driven by training patterns, practice economics, and evidence-practice lag. Your doctor may be doing their best within a system that doesn't support thorough PD care.
Gap 1: Volume-Loss Deformities Go Unassessed
What the evidence says: 65% of PD patients have volume-loss deformities — hourglass (23%), unilateral indentation (39%), and/or distal tapering (13%). These are independently associated with axial instability (OR 3.5), psychological distress (OR 2.6), and decreased sexual activity (OR 2.7) — even after controlling for curvature degree. (Margolin 2018, n=128, retrospective case series)[Chart review]
Volume-loss deformities are also a positive predictor of CCH response (Cahill 2025, n=826, P=.02 — moderate/severe hourglass/indentation predicts 3-10° more curvature improvement than absent or mild). Patients with volume-loss who haven't been assessed may be missing recognition of a feature that favors their CCH outcomes.
Brian's experience: "It's distinctly thinner on top 1/3 with a clear restriction where the problem section is." His urologist did not assess for volume-loss deformities. The Doppler report mentions plaque location and curvature only — no indentation, hourglass, or axial instability assessment.
What to ask your doctor:"Can you assess specifically for hourglass deformity, indentation, and distal tapering? And test for axial instability? I'm noticing [describe what you observe]."
Why this matters: Volume-loss deformities affect treatment selection. Extra-tunical grafting (ETG) may be appropriate for significant indentation. Standard CCH or plication protocols don't address volume loss. If your doctor doesn't look for it, your treatment plan may miss a significant component of your condition.
Discussion
Sign in to comment on Gap 1: Volume-Loss Deformities Go Unassessed.
Gap 2: Non-Standard Treatment Protocols
What the evidence says: 21% of US urologists currently use treatments the AUA explicitly discourages — even among those who say they follow AUA guidelines. (Brant 2023, n=145, physician survey, 1.2% response rate)[Survey — self-report bias; non-respondent skew likely underestimates gap]
Published verapamil injection protocols use biweekly to weekly intervals (Levine 2002 foundational verapamil paper used biweekly × 6 months; Favilla 2017 used weekly × 12 weeks; multiple other protocols in this range). No published protocol uses intervals longer than monthly.
Brian's experience: Received verapamil injections at 3-month intervals — a schedule with zero published support. No modeling protocol prescribed. No traction device recommended.
What to ask your doctor:"Published verapamil protocols use weekly to biweekly intervals. What's the reasoning for a different schedule? And what mechanical adjunct — modeling or traction — is part of the protocol?"
Why this matters: The only double-blind RCT of intralesional verapamil (Favilla 2017, n=140) showed zero curvature change. Even the weak positive uncontrolled data used much higher injection frequency than 3-month intervals. A non-standard protocol based on non-evidence-based treatment compounds the gap.
Discussion
Sign in to comment on Gap 2: Non-Standard Treatment Protocols.
Gap 3: No Treatment Options Discussion
What the evidence says: Only 60% of urologists perform thorough pre-treatment assessment including in-office curvature measurement. Fellowship-trained sexual medicine specialists perform thorough evaluations 85% of the time vs 54% for non-fellowship-trained (P=.003). (Brant 2023, n=145)[Survey]
81% of urologists treating PD have no fellowship training in andrology or sexual medicine. (Brant 2023)[Survey]
Brian's experience: No treatment alternatives were discussed. No mention of CCH (Xiaflex), hyaluronic acid, traction therapy, or surgical options. "Never talked to me about the options. No meeting with him ever took more than 3 minutes."
What to ask your doctor:"What are my treatment options? I'd like to understand the evidence for each — CCH, hyaluronic acid, traction, and surgery — and which one fits my specific situation."
Why this matters: Informed consent requires understanding alternatives. A 3-minute encounter cannot provide meaningful informed consent for a condition with multiple evidence-graded treatment options.
Discussion
Sign in to comment on Gap 3: No Treatment Options Discussion.
Gap 4: Refusing Outside Imaging
What the evidence says: This is a documented systemic pattern across medical specialties — not specific to PD. Outside imaging refusal functions as patient lock-in (billing capture, information asymmetry, scheduling control). (Systemic analysis — no PD-specific survey data)[Expert analysis]
Brian's experience: Another urologist could perform the Doppler in 2 weeks. Brian's urologist refused to accept it, requiring a 3-month wait for his own Doppler. This added 3 months to an already-delayed timeline during which the disease was actively progressing.
What to ask your doctor:"If I've had imaging done elsewhere, will you review and accept it? If not, why not — and how soon can you schedule your own?"
Why this matters: Every month of delay during active-phase PD is a month of potential progression. A 3-month wait for a Doppler that takes minutes to perform delays treatment decisions during the most critical treatment window.
Discussion
Sign in to comment on Gap 4: Refusing Outside Imaging.
Gap 5: Verbal/Written Report Discrepancy
What the evidence says: No specific survey data on verbal vs written discrepancies in PD care. However, verbal clinical communication often diverges from formal documentation — this is a recognized quality concern across all medical specialties.
Brian's experience: His urologist verbally told him there was "some reduced blood flow in some areas." The written Doppler report states all vascular parameters are Normal — arterial diameter, maximum flow, time to peak all normal, venous phase flow minimal (which is the desired finding). The verbal characterization doesn't match the written record.
What to ask your doctor:"Can you walk me through exactly what the Doppler report shows? I want to make sure I understand the written findings, not just the verbal summary."
Why this matters: Treatment decisions should be based on documented findings, not verbal impressions. If something the doctor says doesn't match the report, ask for clarification — one of them is wrong.
Discussion
Sign in to comment on Gap 5: Verbal/Written Report Discrepancy.
Gap 6: Evidence-Practice Lag
What the evidence says: The time for landmark clinical evidence to change clinical practice is documented as substantial across multiple medical specialties (informatics literature on evidence-practice translation lag — citations available on request, not in the 39-paper PD registry). For PD specifically: Favilla 2017 demonstrated zero verapamil curvature benefit in a double-blind RCT — yet verapamil remains widely prescribed in 2025. Brant 2023 (n=145) found 21% of US urologists currently use AUA-discouraged treatments. (Brant 2023 — see Evidence Reference §2.3)[Survey]
Brian's experience: Received verapamil in 2026 — 9 years after the definitive negative trial. The evidence against verapamil curvature efficacy was available since 2017. His urologist's practice pattern reflects the evidence base of ~2010, not 2025.
What to ask your doctor:"What's the most recent evidence you're relying on for this treatment recommendation? I've seen the Favilla 2017 double-blind RCT — how does that factor into your assessment?"
Why this matters: If your doctor's answer references studies from before 2015, or if they're unfamiliar with Favilla 2017 or the IMPRESS trials, they may not be current on PD evidence. This isn't a test — it's a calibration of whether the conversation is happening on the same evidence base.
Discussion
Sign in to comment on Gap 6: Evidence-Practice Lag.
Gap 7: Informed Consent in 3-Minute Encounters
What the evidence says: Meaningful informed consent requires understanding the diagnosis, the proposed treatment, the alternatives, the evidence for and against each, and the risks. For a condition with PD's complexity — multiple treatment options, phase-dependent selection, evidence-graded guidelines with cross-society disagreements — this is structurally impossible in a 3-minute encounter. (W2 analysis; supported by informed consent literature)[Expert analysis]
Brian's experience: "No meeting with him ever took more than 3 minutes." The encounter was too short to provide informed consent by any standard.
What to ask your doctor: This isn't a question for your doctor — it's a signal for you. If your PD encounter takes less than 10 minutes and doesn't include a discussion of alternatives, you may not be receiving care that allows meaningful informed consent. Consider seeking a second opinion from a fellowship-trained sexual medicine specialist.
Discussion
Sign in to comment on Gap 7: Informed Consent in 3-Minute Encounters.
Gap 8: No Mechanical Adjunct With Injectables
What the evidence says: Across multiple CCH studies, mechanical adjunct (modeling, traction) appears to be a necessary component for curvature correction. A separate Phase IIb CCH study (cited via secondary IMPRESS review literature) reported no difference between CCH and placebo in the non-modeling arms; the primary publication for this Phase IIb data is not in our 39-paper registry. Studies with intensive multimodal mechanical adjunct (Capece 2018, n=135) report response rates higher than studies with standard modeling alone (IMPRESS Phase III, 46% composite responder). Note: these are cross-study comparisons with different cohorts and outcome definitions — not a head-to-head trial. (Multiple studies — see Evidence Reference §3.1)[Multiple RCTs + case series]
Brian's experience: Received verapamil injection with no modeling protocol, no traction device recommendation, no stretching instructions. "Never talked to me about" mechanical adjuncts.
What to ask your doctor:"What mechanical adjunct — modeling, traction, or vacuum device — do you prescribe with the injection? How often should I be doing it at home between visits?"
Why this matters: An injectable without mechanical adjunct may be missing the mechanism that produces curvature correction. If your doctor prescribes an injection without specifying a modeling/traction protocol, ask what the evidence says about mechanical adjuncts for that treatment.
Discussion
Sign in to comment on Gap 8: No Mechanical Adjunct With Injectables.
21% currently use AUA-discouraged treatments despite being aware of guidelines
Informed consent gaps
Expert analysis
Structural in short encounters
No mechanical adjunct
Expert analysis from evidence pattern
Unknown; not surveyed
Geographic/practice caveat: Most survey data is US-centric and skewed toward academic medical centers. Community urology practices (like Brian's) may have different gap profiles. Survey response rates are low (Brant 2023: 1.2%), meaning non-responding urologists — who may be less evidence-aware — are underrepresented.
Discussion
Sign in to comment on How common are these gaps?.
Where to go from here
If multiple gaps in this document match your own experience, that's the system — not you failing alone. Three concrete next steps:
Bring this document to a fellowship-trained sexual medicine specialist. Only 19% of urologists treating PD are fellowship-trained, but they're significantly more likely to engage on each of these gaps (Brant 2023: P<.005 for every evidence-based practice measured).
Review Your Guide (Document A) for treatment-specific questions tied to your situation.
If you can't access fellowship-trained care locally, document each gap that applies to your case for the next conversation with any provider. Knowing the gaps is the first step. Acting on them is the next.
This document was researched by a team of specialized AI research agents under human direction. Every factual claim cites a specific published source. The evidence was independently verified by two specialized AI reviewers using structured pair review with documented pushback. This is educational content — not medical advice. Always discuss treatment decisions with your healthcare provider.
Discussion
Sign in to comment on Where to go from here.
Gap 1: Volume-Loss Deformities Go Unassessed
What the evidence says: 65% of PD patients have volume-loss deformities — hourglass (23%), unilateral indentation (39%), and/or distal tapering (13%). These are independently associated with axial instability (OR 3.5), psychological distress (OR 2.6), and decreased sexual activity (OR 2.7) — even after controlling for curvature degree. (Margolin 2018, n=128, retrospective case series)[Chart review]
Volume-loss deformities are also a positive predictor of CCH response (Cahill 2025, n=826, P=.02 — moderate/severe hourglass/indentation predicts 3-10° more curvature improvement than absent or mild). Patients with volume-loss who haven't been assessed may be missing recognition of a feature that favors their CCH outcomes.
Brian's experience: "It's distinctly thinner on top 1/3 with a clear restriction where the problem section is." His urologist did not assess for volume-loss deformities. The Doppler report mentions plaque location and curvature only — no indentation, hourglass, or axial instability assessment.
What to ask your doctor:"Can you assess specifically for hourglass deformity, indentation, and distal tapering? And test for axial instability? I'm noticing [describe what you observe]."
Why this matters: Volume-loss deformities affect treatment selection. Extra-tunical grafting (ETG) may be appropriate for significant indentation. Standard CCH or plication protocols don't address volume loss. If your doctor doesn't look for it, your treatment plan may miss a significant component of your condition.
Gap 2: Non-Standard Treatment Protocols
What the evidence says: 21% of US urologists currently use treatments the AUA explicitly discourages — even among those who say they follow AUA guidelines. (Brant 2023, n=145, physician survey, 1.2% response rate)[Survey — self-report bias; non-respondent skew likely underestimates gap]
Published verapamil injection protocols use biweekly to weekly intervals (Levine 2002 foundational verapamil paper used biweekly × 6 months; Favilla 2017 used weekly × 12 weeks; multiple other protocols in this range). No published protocol uses intervals longer than monthly.
Brian's experience: Received verapamil injections at 3-month intervals — a schedule with zero published support. No modeling protocol prescribed. No traction device recommended.
What to ask your doctor:"Published verapamil protocols use weekly to biweekly intervals. What's the reasoning for a different schedule? And what mechanical adjunct — modeling or traction — is part of the protocol?"
Why this matters: The only double-blind RCT of intralesional verapamil (Favilla 2017, n=140) showed zero curvature change. Even the weak positive uncontrolled data used much higher injection frequency than 3-month intervals. A non-standard protocol based on non-evidence-based treatment compounds the gap.
Gap 3: No Treatment Options Discussion
What the evidence says: Only 60% of urologists perform thorough pre-treatment assessment including in-office curvature measurement. Fellowship-trained sexual medicine specialists perform thorough evaluations 85% of the time vs 54% for non-fellowship-trained (P=.003). (Brant 2023, n=145)[Survey]
81% of urologists treating PD have no fellowship training in andrology or sexual medicine. (Brant 2023)[Survey]
Brian's experience: No treatment alternatives were discussed. No mention of CCH (Xiaflex), hyaluronic acid, traction therapy, or surgical options. "Never talked to me about the options. No meeting with him ever took more than 3 minutes."
What to ask your doctor:"What are my treatment options? I'd like to understand the evidence for each — CCH, hyaluronic acid, traction, and surgery — and which one fits my specific situation."
Why this matters: Informed consent requires understanding alternatives. A 3-minute encounter cannot provide meaningful informed consent for a condition with multiple evidence-graded treatment options.
Gap 4: Refusing Outside Imaging
What the evidence says: This is a documented systemic pattern across medical specialties — not specific to PD. Outside imaging refusal functions as patient lock-in (billing capture, information asymmetry, scheduling control). (Systemic analysis — no PD-specific survey data)[Expert analysis]
Brian's experience: Another urologist could perform the Doppler in 2 weeks. Brian's urologist refused to accept it, requiring a 3-month wait for his own Doppler. This added 3 months to an already-delayed timeline during which the disease was actively progressing.
What to ask your doctor:"If I've had imaging done elsewhere, will you review and accept it? If not, why not — and how soon can you schedule your own?"
Why this matters: Every month of delay during active-phase PD is a month of potential progression. A 3-month wait for a Doppler that takes minutes to perform delays treatment decisions during the most critical treatment window.
Gap 5: Verbal/Written Report Discrepancy
What the evidence says: No specific survey data on verbal vs written discrepancies in PD care. However, verbal clinical communication often diverges from formal documentation — this is a recognized quality concern across all medical specialties.
Brian's experience: His urologist verbally told him there was "some reduced blood flow in some areas." The written Doppler report states all vascular parameters are Normal — arterial diameter, maximum flow, time to peak all normal, venous phase flow minimal (which is the desired finding). The verbal characterization doesn't match the written record.
What to ask your doctor:"Can you walk me through exactly what the Doppler report shows? I want to make sure I understand the written findings, not just the verbal summary."
Why this matters: Treatment decisions should be based on documented findings, not verbal impressions. If something the doctor says doesn't match the report, ask for clarification — one of them is wrong.
Gap 6: Evidence-Practice Lag
What the evidence says: The time for landmark clinical evidence to change clinical practice is documented as substantial across multiple medical specialties (informatics literature on evidence-practice translation lag — citations available on request, not in the 39-paper PD registry). For PD specifically: Favilla 2017 demonstrated zero verapamil curvature benefit in a double-blind RCT — yet verapamil remains widely prescribed in 2025. Brant 2023 (n=145) found 21% of US urologists currently use AUA-discouraged treatments. (Brant 2023 — see Evidence Reference §2.3)[Survey]
Brian's experience: Received verapamil in 2026 — 9 years after the definitive negative trial. The evidence against verapamil curvature efficacy was available since 2017. His urologist's practice pattern reflects the evidence base of ~2010, not 2025.
What to ask your doctor:"What's the most recent evidence you're relying on for this treatment recommendation? I've seen the Favilla 2017 double-blind RCT — how does that factor into your assessment?"
Why this matters: If your doctor's answer references studies from before 2015, or if they're unfamiliar with Favilla 2017 or the IMPRESS trials, they may not be current on PD evidence. This isn't a test — it's a calibration of whether the conversation is happening on the same evidence base.
Gap 7: Informed Consent in 3-Minute Encounters
What the evidence says: Meaningful informed consent requires understanding the diagnosis, the proposed treatment, the alternatives, the evidence for and against each, and the risks. For a condition with PD's complexity — multiple treatment options, phase-dependent selection, evidence-graded guidelines with cross-society disagreements — this is structurally impossible in a 3-minute encounter. (W2 analysis; supported by informed consent literature)[Expert analysis]
Brian's experience: "No meeting with him ever took more than 3 minutes." The encounter was too short to provide informed consent by any standard.
What to ask your doctor: This isn't a question for your doctor — it's a signal for you. If your PD encounter takes less than 10 minutes and doesn't include a discussion of alternatives, you may not be receiving care that allows meaningful informed consent. Consider seeking a second opinion from a fellowship-trained sexual medicine specialist.
Gap 8: No Mechanical Adjunct With Injectables
What the evidence says: Across multiple CCH studies, mechanical adjunct (modeling, traction) appears to be a necessary component for curvature correction. A separate Phase IIb CCH study (cited via secondary IMPRESS review literature) reported no difference between CCH and placebo in the non-modeling arms; the primary publication for this Phase IIb data is not in our 39-paper registry. Studies with intensive multimodal mechanical adjunct (Capece 2018, n=135) report response rates higher than studies with standard modeling alone (IMPRESS Phase III, 46% composite responder). Note: these are cross-study comparisons with different cohorts and outcome definitions — not a head-to-head trial. (Multiple studies — see Evidence Reference §3.1)[Multiple RCTs + case series]
Brian's experience: Received verapamil injection with no modeling protocol, no traction device recommendation, no stretching instructions. "Never talked to me about" mechanical adjuncts.
What to ask your doctor:"What mechanical adjunct — modeling, traction, or vacuum device — do you prescribe with the injection? How often should I be doing it at home between visits?"
Why this matters: An injectable without mechanical adjunct may be missing the mechanism that produces curvature correction. If your doctor prescribes an injection without specifying a modeling/traction protocol, ask what the evidence says about mechanical adjuncts for that treatment.
21% currently use AUA-discouraged treatments despite being aware of guidelines
Informed consent gaps
Expert analysis
Structural in short encounters
No mechanical adjunct
Expert analysis from evidence pattern
Unknown; not surveyed
Geographic/practice caveat: Most survey data is US-centric and skewed toward academic medical centers. Community urology practices (like Brian's) may have different gap profiles. Survey response rates are low (Brant 2023: 1.2%), meaning non-responding urologists — who may be less evidence-aware — are underrepresented.
